Home » Stocks » Graybug Vision

Graybug Vision, Inc. (GRAY)

Stock Price: $15.89 USD -0.42 (-2.58%)
Updated Oct 21, 2020 2:39 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 319.28M
Revenue (ttm) n/a
Net Income (ttm) -34.14M
Shares Out 19.16M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $15.89
Previous Close $16.31
Change ($) -0.42
Change (%) -2.58%
Day's Open 16.67
Day's Range 15.25 - 16.67
Day's Volume 57,010
52-Week Range 12.50 - 20.74

More Stats

Market Cap 319.28M
Enterprise Value 301.74M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.16M
Float 12.62M
EPS (basic) n/a
EPS (diluted) -1.78
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 174,598
Short Ratio 0.27
Short % of Float 1.38%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 20.32
Revenue n/a
Operating Income n/a
Net Income -34.14M
Free Cash Flow n/a
Net Cash 17.54M
Net Cash / Share 0.87
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-37.50-28.57
Net Income-37.04-28.38
Shares Outstanding11.8911.43
Earnings Per Share-3.71-2.86
Operating Cash Flow-31.22-28.22
Capital Expenditures-0.61-1.46
Free Cash Flow-31.82-29.68
Cash & Equivalents35.9612.83
Net Cash / Debt35.9612.83
Book Value-103-66.79
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Graybug Vision, Inc.
Country United States
Employees 24
CEO Frédéric Guerard

Stock Information

Ticker Symbol GRAY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GRAY
IPO Date September 25, 2020


Graybug Vision, a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.